Tag: Sharemarket
Investment Analysis: Mesoblast Ltd (ASX: MSB)
Business Summary Mesoblast Limited specializes in developing allogeneic, “off‑the‑shelf” cellular medicines designed…
ASX IPO outlook 2026, Is it the Year ASX Listings Return?
Australia’s IPO market showed tentative signs of life late in 2025 after…
4DMedical Investment Analysis: (ASX:4DX)
Can Breakthrough Lung Imaging Become a Durable Growth Engine? 4DMedical Limited is…
Market Outlook: An overview on an ASX midcap: A2 Milk
A new source of dairy and pivoting consumer perceptions A2 Milk offers…
Australian ETF Market 2026, Why the ETF Boom Is Reshaping the ASX
Australian ETF Market 2026, Why the ETF Boom Is Reshaping the ASX…
Nick Scali Investment Analysis (ASX: NCK), ANZ Fortress Meets UK Expansion Challenges
This Nick Scali investment analysis examines one of Australia’s most consistently profitable…
Life360 (ASX: 360) Investment Analysis
A Scalable Consumer Platform Positioned for Global Growth Life360 has become one…
ASX Outage Reveals Deeper Failures in Market Infrastructure
When Australia's share market operator can't publish company announcements for more than…
Where Active Still Wins: Why Small-Cap Managers Are Beating The ETFs
Active Isn't Dead, Its Just Smaller While passive investing has swept global…
Retail Rush at the Top? What the ASX’s Hot-Stock Frenzy Means
Retail participation on the ASX jumped through the September quarter as the…